Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children
Status:
Completed
Trial end date:
2019-08-07
Target enrollment:
Participant gender:
Summary
The clinical trial phase 2b is designed to assess the safety and the specific immune response
of the active ingredient (protein + adjuvant) in healthy and then in infected school children
from 8 to 11 years of age with intestinal and/or urinary schistosomiasis, living in the
Valley of the Senegal River, a highly endemic area for schistosomiasis.
Phase:
Phase 2
Details
Lead Sponsor:
Oswaldo Cruz Foundation
Collaborators:
Biomedical Research Center EPLS IDRI Orygen Biotecnologia SA